ModulatIng Cancer therapy RespOnse using Bacterial Extracellular nanovesicles

Introduction

Emerging evidence from cancer patients and mouse models indicates that gut bacteria affect response to immune checkpoint inhibitors (ICI). As a result, modification of gut bacteria by dietary changes, probiotics, and fecal transplantations are explored, but a huge gap remains to gain clinical application.

Limitations

Limiting factors include:

• The lack of mechanistic knowledge on how gut bacteria impact ICI response.
• The need for antibiotics to treat infections in cancer patients.
• Gut resilience to exogenous bacterial colonization.

Bacteria and Extracellular Vesicles

Bacteria release nanometer-sized extracellular vesicles (BEV), loaded with specific pathogen-associated molecular patterns (PAMP), which possess multiple favorable characteristics for clinical application but remain minimally explored in oncology.

Research Discovery

Recently, my research group pioneered the discovery of gut-derived immunomodulatory BEV in the systemic circulation (sysBEV) of non-septicemic cancer patients. I hypothesize that sysBEV direct ICI response by initiating cytokine release to instruct innate and adaptive anti-tumor immunity.

Project Objective

The overall scientific objective of my ERC-CoG project is to establish an innovative nanotherapeutic strategy using non-replicating BEV nanoparticles as a game changer to establish a safe but potent and durable ICI response.

Methodology

Hereto, MICROBE will analyze cancer patient biospecimens to address a number of fundamental questions regarding BEV characteristics that are essential to ICI response. This know-how will be implemented to formulate BEV nanotherapeutics from gut bacteria of healthy donors and ICI responsive cancer patients.

Administration and Synergism

The optimal administration route, treatment dosage, pharmacokinetics, and pharmacodynamics will be established. Additionally, the synergism between BEV nanotherapeutics and ICI will be elucidated using clinically relevant mouse models.

Conclusion

In conclusion, MICROBE will provide the EU a frontrunner position for a future first-in-human clinical trial using BEV nanotherapeutics in anti-cancer treatment.